AdipoPharma

Strasbourg, France · Founded 2017 · Privately Held (backing)

Developer of a peptide-based drug designed to offer treatment for patients suffering from type 2 diabetes. AdipoPharma is based in Strasbourg, France and was founded in 2017. Its last known valuation is $18.4 million. It has raised $34.5 million.

Last price · $/share
—
Implied valuation
$18.4M
Total raised
$34.5M
Last round
—
What is AdipoPharma worth?
$18.4Mlast known valuation
Free account
More of AdipoPharma with a free account
  • ·The complete investor list: 11 names
  • ·Watch AdipoPharma: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

AdipoPharma funding history

No rounds on record

No funding rounds for AdipoPharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

AdipoPharma valuation

AdipoPharma's last known valuation is $18.4 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How AdipoPharma's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For AdipoPharma, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →

Frequently asked about AdipoPharma

What is AdipoPharma worth?
AdipoPharma's last known valuation is $18.4M.
How much has AdipoPharma raised?
AdipoPharma has raised $34.5M in total funding across its recorded rounds.